Porsolt & Metris Sign a Co-Marketing Agreement
News Nov 26, 2009
Porsolt and Partners Pharmacology (Porsolt) and Metris have announced that they have entered into a global co-marketing agreement to promote preclinical screening services using Laboras , a non-invasive technology for automatic and comprehensive in vivo behavioral characterization of drug candidates.
Under this alliance, Porsolt will offer CRO services utilizing the in vivo screening platform to its clients. The Laboras system enables the measurement of multiple behavioral pharmacodynamic endpoints in a single experiment utilizing a high throughput non-invasive system.
Dr. Martine Lemaire, Senior Director - Commercial & Business Development of Porsolt said, “We are thrilled by the synergy between Porsolt’s long-established and recognized expertise in behavioral pharmacology and the high-quality, proven utility of the Laboras innovative technology system.
This partnership has formed in response to the needs expressed by Porsolt’s clients for increased information on drug-like molecules earlier in the drug discovery process. It fits obviously with our strategy to constantly deliver superior quality scientific solutions tailored to our customer’s need.”
How do Poison Frogs Protect Themselves Against Their Own Neurotoxin?News
Scientists are a step closer to resolving a related head-scratcher, how do these frogs keep from poisoning themselves?READ MORE
Unchained Labs Unveils LEA 9 Software Making Workflows EasyNews
Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, released its LEA 9 software, making Freeslate and Junior automation systems way more accessible.READ MORE